Kiniksa appoints Eben Tessari as SVP, Chief Operating Officer

Kiniksa Pharmaceuticals International, plc

Eben Tessari promoted to COO effective Jan 3, 2022; previously SVP Chief Business Officer.
New employment agreement provides $444,960 base salary and 40% target annual bonus.
Severance includes 9 months base salary plus $16,500 lump sum and 12-month equity acceleration.
Tessari also subject to existing invention, non-disclosure, non-competition agreements.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Eben Tessari

SVP, Chief Operating Officer

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2022-01-03
Filed: January 3, 2022, 6:59 PM ET

Effective January 3, 2022, the Board of Directors (the “Board”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”) appointed Eben Tessari as the Company’s SVP, Chief Operating Officer and principal operating officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eben Tessari was appointed as SVP, Chief Operating Officer at Kiniksa Pharmaceuticals International, plc.

Action: appointed
Role: SVP, Chief Operating Officer

Exact text from the filing

Effective January 3, 2022, the Board of Directors (the “Board”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”) appointed Eben Tessari as the Company’s SVP, Chief Operating Officer and principal operating officer.

View on SEC.gov

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-22-000429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.